Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies

Chemoimmunotherapy (CIT) and targeted therapy with single‐agent ibrutinib are both recommended first‐line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. Using ibrutinib data from the RESONATE‐2 (PCYC‐1115/1116) study conducted in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Robak, Tadeusz, Burger, Jan A., Tedeschi, Alessandra, Barr, Paul M., Owen, Carolyn, Bairey, Osnat, Hillmen, Peter, Simpson, David, Grosicki, Sebastian, Devereux, Stephen, McCarthy, Helen, Coutre, Steven E., Quach, Hang, Gaidano, Gianluca, Maslyak, Zvenyslava, Stevens, Don A., Moreno, Carol, Gill, Devinder S., Flinn, Ian W., Gribben, John G., Mokatrin, Ahmad, Cheng, Mei, Styles, Lori, James, Danelle F., Kipps, Thomas J., Ghia, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221114/
https://www.ncbi.nlm.nih.gov/pubmed/30129285
http://dx.doi.org/10.1002/ajh.25259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221114/
https://www.ncbi.nlm.nih.gov/pubmed/30129285
http://dx.doi.org/10.1002/ajh.25259

Ejemplares similares